Recent advances in mantle cell lymphoma

Report of the 2012 Mantle Cell Lymphoma Consortium Workshop

Michael E. Williams, Steven H. Bernstein, Pedro Jares, Brad S. Kahl, Thomas Elmer Witzig, Leo I. Gordon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 and the t(11;14)(q13;q32) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. While a subset of patients have an indolent clinical course, the overall outcome for patients with MCL remains poor. There is no proven curative therapy, and no standard of care has been established for initial or subsequent lines of therapy. Several regimens are highly active in previously untreated patients, and recent research has led to improvements in currently available therapy. Moreover, investigational agents have recently demonstrated promising activity in clinical trials. A workshop was held to review recent data on MCL pathogenesis, novel molecular targets and alternative approaches to immunotherapy, and to discuss recent and ongoing clinical trials in MCL. The presentations are summarized in this article, which is intended to highlight areas of active investigation and identify important avenues for future research.

Original languageEnglish (US)
Pages (from-to)1882-1890
Number of pages9
JournalLeukemia and Lymphoma
Volume54
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Mantle-Cell Lymphoma
Education
Clinical Trials
Genetic Translocation
Cyclin D1
B-Cell Lymphoma
Standard of Care
Non-Hodgkin's Lymphoma
Immunotherapy
Therapeutics
Research

Keywords

  • Immunotherapy
  • Mantle cell lymphoma
  • Pathogenesis
  • Targeted therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Recent advances in mantle cell lymphoma : Report of the 2012 Mantle Cell Lymphoma Consortium Workshop. / Williams, Michael E.; Bernstein, Steven H.; Jares, Pedro; Kahl, Brad S.; Witzig, Thomas Elmer; Gordon, Leo I.

In: Leukemia and Lymphoma, Vol. 54, No. 9, 09.2013, p. 1882-1890.

Research output: Contribution to journalArticle

Williams, Michael E. ; Bernstein, Steven H. ; Jares, Pedro ; Kahl, Brad S. ; Witzig, Thomas Elmer ; Gordon, Leo I. / Recent advances in mantle cell lymphoma : Report of the 2012 Mantle Cell Lymphoma Consortium Workshop. In: Leukemia and Lymphoma. 2013 ; Vol. 54, No. 9. pp. 1882-1890.
@article{14ff0c44e5504a80ad4167d44edc7c61,
title = "Recent advances in mantle cell lymphoma: Report of the 2012 Mantle Cell Lymphoma Consortium Workshop",
abstract = "Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 and the t(11;14)(q13;q32) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. While a subset of patients have an indolent clinical course, the overall outcome for patients with MCL remains poor. There is no proven curative therapy, and no standard of care has been established for initial or subsequent lines of therapy. Several regimens are highly active in previously untreated patients, and recent research has led to improvements in currently available therapy. Moreover, investigational agents have recently demonstrated promising activity in clinical trials. A workshop was held to review recent data on MCL pathogenesis, novel molecular targets and alternative approaches to immunotherapy, and to discuss recent and ongoing clinical trials in MCL. The presentations are summarized in this article, which is intended to highlight areas of active investigation and identify important avenues for future research.",
keywords = "Immunotherapy, Mantle cell lymphoma, Pathogenesis, Targeted therapies",
author = "Williams, {Michael E.} and Bernstein, {Steven H.} and Pedro Jares and Kahl, {Brad S.} and Witzig, {Thomas Elmer} and Gordon, {Leo I.}",
year = "2013",
month = "9",
doi = "10.3109/10428194.2013.771400",
language = "English (US)",
volume = "54",
pages = "1882--1890",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Recent advances in mantle cell lymphoma

T2 - Report of the 2012 Mantle Cell Lymphoma Consortium Workshop

AU - Williams, Michael E.

AU - Bernstein, Steven H.

AU - Jares, Pedro

AU - Kahl, Brad S.

AU - Witzig, Thomas Elmer

AU - Gordon, Leo I.

PY - 2013/9

Y1 - 2013/9

N2 - Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 and the t(11;14)(q13;q32) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. While a subset of patients have an indolent clinical course, the overall outcome for patients with MCL remains poor. There is no proven curative therapy, and no standard of care has been established for initial or subsequent lines of therapy. Several regimens are highly active in previously untreated patients, and recent research has led to improvements in currently available therapy. Moreover, investigational agents have recently demonstrated promising activity in clinical trials. A workshop was held to review recent data on MCL pathogenesis, novel molecular targets and alternative approaches to immunotherapy, and to discuss recent and ongoing clinical trials in MCL. The presentations are summarized in this article, which is intended to highlight areas of active investigation and identify important avenues for future research.

AB - Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 and the t(11;14)(q13;q32) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. While a subset of patients have an indolent clinical course, the overall outcome for patients with MCL remains poor. There is no proven curative therapy, and no standard of care has been established for initial or subsequent lines of therapy. Several regimens are highly active in previously untreated patients, and recent research has led to improvements in currently available therapy. Moreover, investigational agents have recently demonstrated promising activity in clinical trials. A workshop was held to review recent data on MCL pathogenesis, novel molecular targets and alternative approaches to immunotherapy, and to discuss recent and ongoing clinical trials in MCL. The presentations are summarized in this article, which is intended to highlight areas of active investigation and identify important avenues for future research.

KW - Immunotherapy

KW - Mantle cell lymphoma

KW - Pathogenesis

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84883031349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883031349&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.771400

DO - 10.3109/10428194.2013.771400

M3 - Article

VL - 54

SP - 1882

EP - 1890

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -